Facing extinction, Sezzle chopped costs and hit on a strategy for making money from the heaviest users. The stock market noticed.

Around the same time, the prototype of the Squibb logo was designed ... have been submitted to regulatory agencies for approval. Bain Capital has agreed to buy Mitsubishi Tanabe for around ...

Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...

SelectQuote (SLQT) announced that the company signed a $350M strategic investment from funds managed by Bain Capital, Morgan Stanley Private ...

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

Bain Capital will partner with Milacron’s current owner, Hillenbrand, Inc. (NYSE: HI), who will remain a significant investor in the business to accelerate the Company’s continued growth. Bain Capital ...

Independent company plans significant investment in innovation, both internal product development and external licensing and acquisitions, supported by Bain Capital investment Founded in 1678 ...

and we have reached a conclusion that promoting a growth strategy under Bain Capital, which has extensive investment experiences in healthcare, is the best option,” the conglomerate said.

Hillenbrand Inc. has announced the sale of a 51% stake in its Milacron injection molding and extrusion business to an ...

Bain Capital’s global Healthcare platform has deep experience supporting the growth and innovation of global pharmaceutical companies including Aiolos Bio (now part of GSK), Avistone ...

Bain Capital has agreed to acquire Tanabe Pharma, the pharma arm of Mitsubishi Chemical Group Corporation. The deal puts Tanabe Pharma at a valuation of about $3.3 billion. Founded in 1678, Tanabe ...